Insulin glulisine. Aventis Pharma

Curr Opin Investig Drugs. 2003 Oct;4(10):1240-4.

Abstract

Aventis Pharma (formerly Hoechst Marion Roussel) is developing insulin glulisine, a fast-acting insulin analog, for the potential treatment of hyperglycemia in both type 1 and 2 diabetes. Aventis has submitted an NDA and an MAA to the FDA and the EMEA, respectively.

Publication types

  • Review

MeSH terms

  • Animals
  • Clinical Trials, Phase II as Topic
  • Clinical Trials, Phase III as Topic
  • Diabetes Mellitus, Type 1 / drug therapy*
  • Diabetes Mellitus, Type 2 / drug therapy*
  • Humans
  • Hypoglycemic Agents / adverse effects
  • Hypoglycemic Agents / chemical synthesis
  • Hypoglycemic Agents / pharmacokinetics
  • Hypoglycemic Agents / therapeutic use*
  • Insulin / adverse effects
  • Insulin / analogs & derivatives
  • Insulin / chemical synthesis
  • Insulin / pharmacokinetics
  • Insulin / therapeutic use*
  • Structure-Activity Relationship

Substances

  • Hypoglycemic Agents
  • Insulin
  • insulin glulisine